semaj83/ctmatch_classification huggingface dataset:
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Obesity Diabetes Normal weight Healthy Normal sleep times  Sleep disorders Overweight Diabetes Other health conditions Excessive caffeine and alcohol intake Smoking
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Major Depressive Disorder Adults between ages 18 to 64 years who meet the for a depressive episode as measured by a score of ≥ 16 on first 17 items of HAM-D (Urdu version Patients with low normal B12 levels in serum (>191 but < 300 pg/ml) Those who will provide informed consent  Patients with concurrent unstable medical illness History of manic episodes or psychotic illness Psychotic symptoms within depressive episode
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 14.0-19.0,  Community Adolescents at Risk for Depression and Suicide willing to participate group assignment and grant consents  unwilling to participate potential group activity and grant consents severe physical or psychiatric disorders
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Serotonin Syndrome Male or female patients with a diagnosis of PD Rasagiline treatment as mono or adjunct therapy for PD with concomitant antidepressant medication (SSRIs, SNRIs, St. John's wort and/or TCAs) at any time during the specified review period, OR Rasagiline treatment as mono or adjunct therapy for PD without concomitant antidepressant medication (SSRIs, SNRIs, St. John's wort and/or TCAs) at any time during the specified review period. OR Antidepressant therapy (SSRIs, SNRIs, St. John's wort and/or TCAs) and any other dopaminergic anti-PD treatment besides rasagiline or selegiline at any time during the specified review period Willing to consent to review of office chart and to review of records of ER visits and/or hospitalizations corresponding to the review window, if required Patients previously participating in a rasagiline clinical trial (and their follow-up protocols) are eligible, provided that they did not receive antidepressant therapy during trial participation In addition to the above each group has specific stated below Group R+AD: Enrollment in this group requires that patients must have taken rasagiline and an antidepressant (SSRIs, SNRIs, St. John's wort and/or TCAs, regardless of indication) within 14 days of each other (or five weeks, if fluoxetine preceded rasagiline) Group R: Enrollment in this group requires patients must have at least 2 months of rasagiline use Group AD: Patients must be taking an approved dopaminergic medication for PD. Enrollment in this group requires that patients must have at least 2 months of treatment with an antidepressant medication  Use of rasagiline for any indication other than PD Patients taking a monoamine oxidase inhibitor (MAOI) antidepressant and/or selegiline Inability or unwillingness to request records of ER visits and/or hospitalizations corresponding to the review period
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Major Depressive Disorder Diagnosis of Major Depressive Disorder Allowed comorbidities: Dysthymia, Anxiety Disorders years old or older Males + Females English-speaking Women of reproductive age must be on adequate birth control, either oral contraceptives or using condoms or other barrier methods with spermicidal agents Subjects may be undergoing psychotherapy, but must maintain current psychotherapy status. Must not start therapy if not already in therapy. If in therapy, must have received at least 6 sessions prior to entering the study Subjects may continue taking herbals or supplements during the study, but they may not start any new herbals or supplements during the study  or more failed trials of antidepressants (adequate dose and duration, and documented) Substance dependence in the past 6 months Current substance use or abuse (MJ, benzodiazepines, narcotics). If BZD use, patient must be tapered off and wait 1 month before being included in the trial Psychosis Bipolar Affective Disorder Type I, II or NOS Pregnancy (current or planned) Unstable medical illness (pt has to be stable for at least 3 months, and may be excluded per investigator discretion) Dementia Mental retardation Traumatic Brain Injury
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Cancer Male patients with any advanced cancer (metastatic or locally recurrent) who have a bioavailable testosterone (BT) of < 70 ng/dL Male patients who have fatigue present every day for the last two weeks and have an Edmonton Symptom Assessment System (ESAS) fatigue score during the last 24 hours of >/= to 4 on a 0 to 10 scale (in which 0 = no fatigue and 10 = worst possible fatigue) Male patients who are willing to receive intramuscular injections every 2 weeks and are 18 years of age or older are eligible for this study Participants must be willing to have blood samples drawn at screening and/or baseline and every two weeks until the end of treatment Prostatic Specific Antigen (PSA) level must be lower than 4.0 ng/mL to be eligible for this study and Digital Rectal Exam (DRE) must be normal ECOG PS </= 3 and participants must be able to stand up with or without assistance and to ambulate Hemoglobin (Hgb) >/= 9 g/dL. If the patient has not had blood drawn for a hemoglobin level in the past 28 days, one will be done to determine eligibility. Patients with a hemoglobin < 9 g/dL will be referred for treatment of their anemia  Patients who are determined incapable of completing questionnaires due to cognitive or physical deficits are ineligible for this study Abnormal Digital Rectal Exam (DRE) at baseline or history of severe untreated benign prostatic hypertrophy (BPH) with International Prostatic Symptom Score (IPSS) >19 Patients with a history of prostate cancer, a history of breast cancer or adenocarcinoma of unknown origin A history of untreated obstructive sleep apnea Uncontrolled severe heart failure (NYHA Class III or IV), uncontrolled cardiac arrhythmia or severe COPD requiring home oxygen Patients who have evidence of pre-existing hypopituitarism/hypogonadism including status post bilateral orchiectomy, for which replacement therapy is mandated, are ineligible for this study Patients exhibiting clinically diagnosed severe dehydration are ineligible Patients with a history of uncontrolled arrhythmia Patients who are currently receiving androgen therapy or dehydroepiandrosterone (DHEA) Diabetics with a history of frequent episodes of hypoglycemia or uncontrolled diabetes mellitus (DM) defined as a fasting glucose over 200 mg/dL or HbA1c above 8%
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Self Concept Body Fat Composition Depression Perceived Social Support Healthy males aged 18-40 years Available twice a week for 10 weeks and willing to participate in moderate intensity exercise for 50 minutes at each session Not regularly physically active (i.e., engages in a structured exercise session once or less per week) Willing to participate in the internet-based CBT intervention once per week for 10 weeks  Current illness or history of clinical conditions that prevents participation in exercise Currently alcohol/drug abusing Major cognitive or psychiatric impairments Currently receiving medication for major psychiatric disorders, including depression
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  Breast Cancer over the age of 25 enrolled in one of the following protocols IRB # 08-005522: Evaluation of Molecular Breast Imaging in Patients with a High Likelihood of Ductal Carcinoma in Situ. 07-004241: Molecular Breast Imaging in the Preoperative Evaluation of Women with Biopsy Proven Breast Cancer. 1204-03: Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients with Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ. 07-003397: Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation. 17-05: Determination of the Sensitivity of a Dual-Headed Small Field of View Gamma Camera for the Detection of Small Breast Lesions Digital mammogram at the Mayo Clinic within the past 30 days  They are unable to understand and sign the consent form They are pregnant or lactating They are physically unable to sit upright and still for 40 minutes Recently enrolled on one of the ongoing tomosynthesis vs. mammography studies (rationale avoid performing duplicate tomosynthesis studies in the same patient)
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anemia years or older Diagnosis of low or intermediate-1 risk Myelodysplastic (MDS) with any chromosome karyotype except del 5q[31] Anemia that requires red blood cell transfusions Resistant to erythropoiesis stimulating agents (ESAs) or blood erythropoietin level > 500 mU/mL Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 Must agree to follow pregnancy precautions as required by the protocol Must agree to receive counseling related to teratogenic and other risks of lenalidomide Must agree not to donate blood or semen Must be willing to consent to two or more bone marrow aspirate procedures to be completed during study  Subjects previously receiving immunomodulating or immunosuppressive agents, or epigenetic or deoxyribonucleic acid (DNA) modulation agents Allergic reaction to thalidomide Renal insufficiency creatinine clearance (CrC1)<40 mL/min by Cockcroft-Gault method) Prior history of cancer, other than MDS, unless the subject has been free of the disease for ≥ 5 years. (Basal cell carcinoma of the skin, carcinoma in situ of the cervix, or stage Tumor (T) 1a or T1b prostate cancer is allowed) Absolute neutrophil count (ANC) < 500/uL Platelets < 50,000/uL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3X upper limit of normal Uncontrolled hyperthyroidism or hypothyroidism Significant neuropathy Prior stem cell transplantation
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 8.0-11.0,  Sleep Obesity Age 8-11 years old BMI for age and gender > 5th percentile (but no greater than 100% overweight) Sleep approximately 9-10 hours nightly Attend elementary school Like at least 1 food and 1 activity used in the reinforcement paradigm Able to understand and complete the reinforcement paradigm  Existence of a diagnosable sleep disorder Medical or psychiatric condition that could influence sleep or weight Onset of menarche Inability to complete study materials, including diagnosed disabilities Dietary restrictions/allergies to foods used in the study that preclude them from study participation
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Depression and over with chronic pain and score of 27 or higher on CES-D scale  or younger, no chronic pain cognitively unable to participate in programming
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Acute Myeloid Leukemia Diagnosis of one of the following Newly diagnosed de novo acute myeloid leukemia (AML) AML secondary to myelodysplastic syndromes (MDS) AML secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years Bone marrow blasts >30% Age ≥ 65 years Easter Cooperative Oncology Group (ECOG) 0-2  Previous cytotoxic or biologic treatment for AML (except hydroxyurea) Previous treatment with azacitidine, decitabine or cytarabine Prior use of targeted therapy agents (e.g., FLT3 inhibitors, other kinase inhibitors) AML French American British subtype (FAB M3) AML associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes Prior bone marrow or stem cell transplantation Candidate for allogeneic bone marrow or stem cell transplant Diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, "in-situ" carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure) Malignant hepatic tumors Uncontrolled systemic infection
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Depressive Disorder Cancer   Cancers diagnosed within 12 months of initiation (i.e., new use) of antidepressant pharmacotherapy will be excluded to account for a minimum period for the development of cancer (cancer latency) and to be consistent with other studies of antidepressants and cancer Patients with a history of any cancer (cancer diagnosis recorded in the tumor registries anytime before the first antidepressant prescription recorded during the study period) Any antidepressant use within 6 months of January 1, 1996
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Gastroesophageal Disease Male/Female or more episodes of heartburn a week for last 3 months  Previous upper GI surgery Underlying co-morbidity Narcotic medications Psychotropic's and Benzodiazapines medications Hx of psychological abnormalities Hx of ETOH in previous 6 mos Diabetes Mellitus Neuropathy Seizures Sleep Apnea
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 16.0-25.0,  Depression A score of 19 or more on the Beck Depression Inventory Currently enrolled at the University of Santo Tomas Able to read, understand, and complete forms
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Depression Overweight Adolescents must: 1) be between the ages of 12 and 18 years (18 year olds must still be in high school and living at home); 2) be at or above the 85th percentile with reference to age and gender-specific Body Mass Index (BMI); 3) have at least one parent available to participate in the treatment protocol; 4) speak English; 5) agree to study participation and random assignment; and 6) be available for follow-up. In order to meet the depressed mood criterion, adolescents must have a primary diagnosis of major depressive disorder (single or recurrent), based on the KSADS-PL with a CGI-Severity ≥ 3 for depression and CDRS ≥ 36. Participants must be healthy, as established by their primary care physician, in order to participate in the exercise program -  Adolescents will be excluded if: 1) they are currently receiving psychotherapy or participating in another weight loss program (only can have been in a weight loss program in the past); 2) they have a medical condition that would interfere with the prescribed dietary plan or participation in physical activity; 3) they are developmentally delayed such that the intervention materials will not be appropriate; 4) they are actively suicidal at intake; 5) they have not been on a stable dose of a psychostimulant for 6 months to ensure that a recently prescribed psychostimulant is not contributing to weight loss; 6) teens on an SSRI will not be allowed to participate due to potential effects of medication on weight loss; 7) they have a substance abuse or dependence diagnosis; or 8) they have failed a medication or psychotherapy trial for depression in the past